Podcast: Molecule to Market: Inside the outsourcing space
Episode: “A Sterling, CDMO Leader” — Episode 180 Apple Podcasts
Host: Raman Sehgal
Guest: Kevin Cook, CEO at Sterling Pharma Solutions Apple Podcasts
Original Episode Link: Episode 180 – A Sterling, CDMO Leader Apple Podcasts
1. Executive Summary
In this episode, Kevin Cook describes his journey in small-molecule manufacturing spanning decades, and how he re-positioned Sterling Pharma Solutions as a global CDMO. The conversation covers strategic decisions around M&A, facility integration, culture transformation, and how the company scaled from one site to a multi-site, cross-border operation. For CDMOs and their sponsors alike, the story offers valuable lessons on growth strategy, operational excellence, and competitive differentiation in an evolving market.
2. Key Takeaways for CDMOs
- M&A as a growth lever: Cook shares his five-point M&A playbook that helped drive transatlantic expansion and build scale. Apple Podcasts
- Culture and people matter: Scaling from ~180 to 1,300+ employees across six sites required deep focus on culture, leadership and organisational alignment. Apple Podcasts
- On-shoring and niche capability: Small molecule manufacturing is seeing a shift back to Western markets, and specialization (e.g., niche APIs) can offer meaningful differentiation. Apple Podcasts
- Relentless operational execution: It’s not just about capacity — CDMOs must execute on quality, timeline, global footprint and client intimacy to win.
3. What This Means for the Industry
This episode highlights that CDMOs, especially in small molecules, are no longer just capacity providers — they’re strategic partners. Growth is built not only through scale, but through smart acquisitions, talent investment, and operational tightening. As sponsors demand faster timelines, higher quality, and global reach, CDMOs that can show thoughtful strategy-backed growth will have the edge.
4. CDMOWorld Commentary
From the vantage of CDMOWorld, Sterling’s evolution underscores a few critical realities:
- CDMOs must be proactive about growth, not just reactive to demand.
- Talent and culture are often the rate-limiting step, not equipment or sites.
- The western small-molecule space is still ripe for on-shoring, and those who can combine scale with flexibility will win.
- For sponsors, partnering with a CDMO that has proven through scale, culture, and global integration provides less risk as modal and geographic complexity increases.
5. Useful Links
- Molecule to Market Podcast Homepage
- Related CDMOWorld article: “Why On-Shoring API Capacity is Back” (link internally)
- Related CDMOWorld article: “The Five M&A Playbook Steps for CDMOs” (link internally)
Source: Molecule to Market (© Raman Sehgal et al.). Summary and commentary by CDMOWorld.com.
If you’d like, I c
Pharma Podcast Picks – Episode Summary
Podcast: Molecule to Market: Inside the outsourcing space
Episode: “A Sterling, CDMO Leader” — Episode 180
Host: Raman Sehgal
Guest: Kevin Cook, CEO at Sterling Pharma Solutions
Original Episode Link: Episode 180 – A Sterling, CDMO Leader Apple Podcasts
1. Executive Summary
In this episode, Kevin Cook describes his journey in small-molecule manufacturing spanning decades, and how he re-positioned Sterling Pharma Solutions as a global CDMO. The conversation covers strategic decisions around M&A, facility integration, culture transformation, and how the company scaled from one site to a multi-site, cross-border operation. For CDMOs and their sponsors alike, the story offers valuable lessons on growth strategy, operational excellence, and competitive differentiation in an evolving market.
2. Key Takeaways for CDMOs
- M&A as a growth lever: Cook shares his five-point M&A playbook that helped drive transatlantic expansion and build scale. Culture and people matter: Scaling from ~180 to 1,300+ employees across six sites required deep focus on culture, leadership and organisational alignment.
- On-shoring and niche capability: Small molecule manufacturing is seeing a shift back to Western markets, and specialization (e.g., niche APIs) can offer meaningful differentiation.
- Relentless operational execution: It’s not just about capacity — CDMOs must execute on quality, timeline, global footprint and client intimacy to win.
3. What This Means for the Industry
This episode highlights that CDMOs, especially in small molecules, are no longer just capacity providers — they’re strategic partners. Growth is built not only through scale, but through smart acquisitions, talent investment, and operational tightening. As sponsors demand faster timelines, higher quality, and global reach, CDMOs that can show thoughtful strategy-backed growth will have the edge.
4. CDMOWorld Commentary
From the vantage of CDMOWorld, Sterling’s evolution underscores a few critical realities:
- CDMOs must be proactive about growth, not just reactive to demand.
- Talent and culture are often the rate-limiting step, not equipment or sites.
- The western small-molecule space is still ripe for on-shoring, and those who can combine scale with flexibility will win.
- For sponsors, partnering with a CDMO that has proven through scale, culture, and global integration provides less risk as modal and geographic complexity increases.
5. Useful Links
- Molecule to Market Podcast Homepage
- Related CDMOWorld article: “Why On-Shoring API Capacity is Back”
- Related CDMOWorld article: “The Five M&A Playbook Steps for CDMOs”
Source: Molecule to Market (© Raman Sehgal et al.). Summary and commentary by CDMOWorld.com.
If you’d like, I c